Zai Lab (ZLAB) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.46
- Estimate
- -$0.65
- Surprise
- +28.9%
- Revenue (period 2026-06-30)
- $105.8M
- Score today
- 4.4/10
Revenue source: xbrl.
How the report landed
Zai Lab (ZLAB) reported a narrower loss than forecast — diluted EPS of -$0.46 against the -$0.65 estimate (a 28.9% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates ZLAB Sell at 4.4/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +28.9% surprise compares with a +5.9% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Geographic: mainland China
- Quality below floor (1.5 < 4.0)
- Momentum score 3.3/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $26.23
- Price target
- $28.83
- Stop
- $24.39
- Upside to target
- +9.9%
- Reward-to-risk
- 0.7:1
Model outputs from TrendMatrix’s engine as of 2026-09-06 — shown for context, not personalized investment advice.
ZLAB at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.94B
- P/E (fwd)
- -12.4
- 52-week range
- $15.96–$34.72
- Off 52-week high
- 24.5%
- RSI (14)
- 54
- Volume vs avg
- 0.63×
- Score today
- 4.4/10